NASDAQ:RXST • US78349D1072
The current stock price of RXST is 8.43 USD. In the past month the price decreased by -15.58%. In the past year, price decreased by -71.62%.
ChartMill assigns a fundamental rating of 3 / 10 to RXST. RXST scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months RXST reported a non-GAAP Earnings per Share(EPS) of -0.88. The EPS decreased by -6.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.58% | ||
| ROE | -12.95% | ||
| Debt/Equity | 0 |
16 analysts have analysed RXST and the average price target is 10.6 USD. This implies a price increase of 25.7% is expected in the next year compared to the current price of 8.43.
For the next year, analysts expect an EPS growth of -50.51% and a revenue growth -6% for RXST
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| MDLN | MEDLINE INC-CL A | 33.38 | 62.533B | ||
| COO | COOPER COS INC/THE | 18.31 | 16.4B | ||
| ALGN | ALIGN TECHNOLOGY INC | 16.88 | 13.589B | ||
| SOLV | SOLVENTUM CORP | 11.2 | 12.768B | ||
| LNTH | LANTHEUS HOLDINGS INC | 13.09 | 4.853B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 19.99 | 4.852B | ||
| ICUI | ICU MEDICAL INC | 18.54 | 3.697B | ||
| HAE | HAEMONETICS CORP/MASS | 11.18 | 2.819B | ||
| XRAY | DENTSPLY SIRONA INC | 8 | 2.498B | ||
| NEOG | NEOGEN CORP | 33.04 | 2.388B |
View all stocks in the Health Care Supplies Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. The company is headquartered in Aliso Viejo, California and currently employs 498 full-time employees. The company went IPO on 2021-07-30. The firm's proprietary RxSight Light Adjustable Lens system (RxSight system) is commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system consists of its RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient's desired vision outcomes.
RXSIGHT INC
100 Columbia Street, Suite 120
Aliso Viejo CALIFORNIA US
CEO: Ron Kurtz
Employees: 498
Phone: 19495217822
RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. The company is headquartered in Aliso Viejo, California and currently employs 498 full-time employees. The company went IPO on 2021-07-30. The firm's proprietary RxSight Light Adjustable Lens system (RxSight system) is commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system consists of its RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient's desired vision outcomes.
The current stock price of RXST is 8.43 USD. The price increased by 0.36% in the last trading session.
RXST does not pay a dividend.
RXST has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
The Revenue of RXSIGHT INC (RXST) is expected to decline by -6% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
RXSIGHT INC (RXST) has a market capitalization of 346.64M USD. This makes RXST a Small Cap stock.
The outstanding short interest for RXSIGHT INC (RXST) is 10.76% of its float.